Massive Bio Stock

Massive Bio is an AI powered oncology platform that connects patients to clinical trials while enabling pharma to get access to patients.

Sign up today and learn more about Massive Bio Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Massive Bio Stock

Massive Bio, is an Artificial Intelligence (AI) powered platform that connects cancer patients and their treating oncologists to clinical trials while enabling pharmaceutical companies to get access to patients, mostly in community practices, and their information to speed up drug development. Massive Bio combines technology, services and oncology sub-specialist expertise to maximize trial enrollment. Massive Bio is the first company that attacks controlling patient enrollment value chain; Massive Bio does patient identification through direct direct and indirect patient acquisition channels, pre-screening through virtual site, Just-In-Time (JIT) site activation and further analyzes real world data for drug discovery. One of the major differentiating point of Massive Bio is that the Company tackles “last mile” issues for trial enrollment to eliminate site and/or financial considerations of patients. Massive Bio is the go to partner for pharmaceutical companies and CROs to get the right patient at the right time.

Funding History

July 2016$900K
July 2018$1.1M
May 2019$2.0M
November 2020$2.8M
June 2022$16.5M


CEO & Co-Founder

Selin Kurnaz

Co-Founder & Chief Medical Officer

Arturo Loaiza-Bonilla

Co-Founder & CTO

Cagatay Culcuoglu

Chief of Community Oncology

Belisario Arango

Board of Directors

Kenan Turnacioglu


Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: